Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the third quarter ending September 30, 2026, and provided a corporate update.
Covered in this story
Call it yourself
No calls on $JBIO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Jade Biosciences Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.